Clinical trials
Follow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Company intelligence / Profile preview
Neurame
Philadelphia, Pennsylvania, United Statesneurame.com ↗
- Ownership
- Private
- Development stage
- Other
01
Overview
Neurame is a pre-clinical stage biotechnology company focused on developing novel therapies for neurodegenerative diseases by leveraging a proprietary protein disaggregase platform. The company's core technology centers on engineered versions of the yeast protein Hsp104, which are designed to selectively dissolve toxic protein aggregates associated with conditions such as ALS, Parkinson's, and Alzheimer's. By targeting the underlying protein misfolding pathology, Neurame aims to restore cellular health and halt disease progression in patients with limited treatment options. The company was founded by leading researchers in the field of protein folding and neurodegeneration from the University of Pennsylvania.
- Therapeutic areas
- Neurology
- Modalities
- Small moleculeProtein
- Industry
- Biotech
Beyond the preview
Go deeper on Neurame.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Licensing & deals
Explore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Trace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Compare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Explore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Connect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Neurame.